http://ift.tt/eA8V8J
Shares of Exact Sciences (EXAS) are soaring today after the maker of a colon cancer test reported financial results that beat across the board.
Exact Sciences reported a loss of 32 cents a share, beating forecasts for a loss of 41 cents, on sales of $8.4 million, ahead of estimates for $37.29 million. But that was only the beginning of the good news for Exact. Cowen’s Doug Schenkel and team explain:
April 27, 2017 at 07:58PM
from Ben Levisohn
No comments:
Post a Comment